Prevent efficacy pool: prevent cancer preclinical drug development program
Ended Awarded Last action
- Contract number
- 75N91021F00001
- Awardee
-
University Of Oklahoma UEI GY8NMUZQXVS7 Part of University Of Oklahoma
- Awarding agency
-
National Cancer Institute
National Institutes of Health, Department of Health and Human Services
- Obligated
- $911,531
Award facts
- Opportunity
-
- TORFP2021E01 Solicitation number
- Contract value 100% obligated
- $911,531.00 Current and potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- NAICS code
- 541714 Research and Development in Biotechnology (except Nanobiotechnology)
- Set-aside
- No set-aside
- Competition
- Full and Open Competition · 1 offer Multiple Award, Fair Opportunity
- Pricing
- Firm Fixed Price
- Place of performance
- Oklahoma City, OK 73104, USA
- Legislative mandates
-
- Walsh-Healey Public Contracts Act FAR subpart 22.6
- Employment Eligibility Verification (E-Verify) FAR subpart 22.18
- Service Contract Inventory FAR subpart 4.17
Award details come from SAM.gov/FPDS.
Transactions
| Action | Obligated | Date |
|---|---|---|
| Supplemental Agreement for work within scope | $0 | |
| Supplemental Agreement for work within scope | $0 | |
| Original award | $911,531 |
About this award
The University of Oklahoma is the prime contractor on a $911,531 firm fixed price delivery order against the PREVENT Preclinical Drug Development Program IDIQ vehicle held by the National Cancer Institute. The scope of work involves testing the efficacy of combination KRAS or EGFR peptide vaccines and the investigational drug CA-170 to improve immunoprevention against lung tumor progression driven by specific mutations in transgenic animal models. Objectives include determining tolerability and dosing of aerosolized CA-170, evaluating vaccine efficacy alone and combined with CA-170 using genetically engineered mouse models of lung tumorigenesis, and establishing immune correlates. Key subcontractor the Methodist Hospital will support the animal studies. The overall goal is to advance development of immunopreventive approaches for lung cancer under the National Cancer Institute's PREVENT program.
Quick answers
Who was awarded contract 75N91021F00001?
75N91021F00001 was awarded to University Of Oklahoma by National Cancer Institute (National Institutes of Health) on May 24, 2021.
How much is contract 75N91021F00001 worth?
The government has obligated $911,531 on 75N91021F00001.
Is contract 75N91021F00001 an order under another contract?
Yes. 75N91021F00001 is a delivery order under 75N91019D00020, an indefinite delivery contract, on PREVENT Preclinical Drug Development Program (PREVENT).
Was contract 75N91021F00001 competed?
The extent of competition for 75N91021F00001 was full and open competition. The government received 1 offer.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award